

DRAFT

**Antiviral (Hep C agents)**

**Clinical criteria apply to all drugs listed below**

<b>Preferred</b>	<b>Non-Preferred</b>
<b><u>All genotypes without cirrhosis</u></b>	
Mavyret™ Tablet (8 weeks of therapy)	Epclusa® Tablet
sofobuvir-velpatasvir tablet (generic for Epclusa® Tablet)	Harvoni® Tablet
	ledipasvir-sofosbuvir tablet (generic for Harvoni® Tablet)
<b><u>All genotypes with compensated cirrhosis (Child Pugh-A)</u></b>	
Mavyret™ Tablet (Up to 12 weeks of therapy)	Sovaldi® Tablet
sofobuvir-velpatasvir tablet (generic for Epclusa® Tablet)	Viekira™ Pak
	Zepatier® Tablet
<b><u>All genotypes previously treated with an HCV regimen containing an NS5A inhibitor or genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor.</u></b>	
Vosevi™	
<b><u>All genotypes with decompensated cirrhosis</u></b>	
sofobuvir-velpatasvir tablet (generic for Epclusa® Tablet)	